Immunocore Holdings plc (FRA:6YG)

Market Cap	1.30B -0.6%
Revenue (ttm)	340.69M +29.0%
Net Income	-30.25M
EPS	-0.60
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	26.00
Previous Close	25.80
Day's Range	25.00 - 26.00
52-Week Range	20.80 - 35.60
Beta	n/a
RSI	37.14
Earnings Date	May 7, 2026

About Immunocore Holdings

Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. It also develops oncology programs, including tebentafusp which is in Phase 3 clinical trial for the treatment of advanced cutaneous melanoma and adjuvant uveal melanoma; brenetafusp which is in Phase ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1999
• Employees: 524
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 6YG

Financial Performance

In 2025, Immunocore Holdings's revenue was $400.02 million, an increase of 28.95% compared to the previous year's $310.20 million. Losses were -$35.51 million, -30.48% less than in 2024.

Financial numbers in USD